UBS Group
QNRX

UBS Group’s Quoin Pharmaceuticals QNRX Stock Holding History

UBS Group’s Portfolio QNRX Stock Details QNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.6K Buy
2,512
+2,495
+14,676% +$22.6K ﹤0.01% 8067
2025
Q4 		$245 Buy
17
+16
+1,600% +$218 ﹤0.01% 10082
2025
Q3 		$7 Sell
1
-129
-99% -$1K ﹤0.01% 10216
2025
Q2 		$1.2K Sell
130
-6,136
-98% -$47K ﹤0.01% 9662
2025
Q1 		$49.1K Buy
6,266
+6,130
+4,507% +$80.6K ﹤0.01% 7610
2024
Q4 		$3.11K Sell
136
-516
-79% -$11.8K ﹤0.01% 8934
2024
Q3 		$11.3K Buy
652
+478
+275% +$10.1K ﹤0.01% 7685
2024
Q2 		$3.54K Buy
174
+28
+19% +$711 ﹤0.01% 8203
2024
Q1 		$4.85K Buy
+146
New +$14.4K ﹤0.01% 7585
2023
Q4 		– Sell
-23
Closed -$3.4K – 9778
2023
Q3 		$3.4K Buy
+23
New +$4.78K ﹤0.01% 7565
2023
Q2 		– Sell
-16
Closed -$3.12K – 9489
2023
Q1 		$3.12K Buy
+16
New +$7.81K ﹤0.01% 8377
2022
Q4 		– Sell
-25
Closed -$24K – 11058
2022
Q3 		$24K Buy
25
+23
+1,150% +$47.3K ﹤0.01% 7154
2022
Q2 		$4K Buy
+2
New +$7.96K ﹤0.01% 9105
2022
Q1 		– Hold
0
– – – 10780
2021
Q4 		– Hold
0
– – – 10610
2021
Q3 		– Hold
0
– -$31K – 9978
2021
Q2 		– Hold
0
– – – 6888
2021
Q1 		– Hold
0
– – – 8249
2020
Q4 		– Sell
-1
Closed -$34K – 8677
2020
Q3 		$34K Hold
1
– – ﹤0.01% 5913
2020
Q2 		$54K Buy
+1
New +$57.7K ﹤0.01% 5791
2020
Q1 		– Hold
0
– – – 7086
2019
Q4 		– Hold
0
– – – 7975
2019
Q3 		– Hold
0
– – – 7649
2019
Q2 		– Hold
0
– – – 7249
2019
Q1 		– Hold
0
– – – 7559
2018
Q3 		– Hold
0
– -$11K – 8205
2018
Q2 		– Hold
0
– – – 7080
2017
Q4 		– Hold
0
– -$27K – 8044
2017
Q3 		– Hold
0
– – – 6245
2017
Q2 		– Hold
0
– – – 6552
2017
Q1 		– Hold
0
– -$5K – 7902
2016
Q4 		– Hold
0
– – – 7249
2016
Q3 		– Hold
0
– – – 7295

Other funds holding QNRX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

UBS Group's QNRX Position: Q1 2026 in Review

UBS Group increased its Quoin Pharmaceuticals (QNRX) stake by 14,676% in Q1 2026, buying an estimated $22.6K and bringing the position to 2,512 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #8067.

UBS Group first reported a position in QNRX in Q2 2020 and has held it in 15 quarters since. The position peaked at $54K in Q2 2020. 22 funds tracked by Wall St. Rank hold QNRX as of Q1 2026.

  • UBS Group held 2,512 shares of Quoin Pharmaceuticals worth $16.6K as of Q1 2026.
  • UBS Group bought 2,495 Quoin Pharmaceuticals shares in Q1 2026, an estimated $22.6K.
  • Quoin Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8067 holding.
  • UBS Group first reported a position in Quoin Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
  • UBS Group's Quoin Pharmaceuticals position peaked at $54K in Q2 2020.
  • 22 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.